当前位置:
X-MOL 学术
›
Trends Endocrin. Met.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Trends in Endocrinology & Metabolism ( IF 10.9 ) Pub Date : 2020-02-01 , DOI: 10.1016/j.tem.2019.11.007 Jennifer R Snaith 1 , Deborah J Holmes-Walker 2 , Jerry R Greenfield 3
Trends in Endocrinology & Metabolism ( IF 10.9 ) Pub Date : 2020-02-01 , DOI: 10.1016/j.tem.2019.11.007 Jennifer R Snaith 1 , Deborah J Holmes-Walker 2 , Jerry R Greenfield 3
Affiliation
Individuals with type 1 diabetes (T1D) frequently fail to achieve glycemic goals and have excess cardiovascular risk and premature death. Adjunctive agents may play a role in reducing morbidity, mortality, and the adverse sequelae of insulin treatment. A surge in type 2 diabetes drug development has revealed agents with benefits beyond glucose lowering, including cardiovascular risk reduction. Could these benefits translate to T1D? Specific trials for T1D demonstrate substantial hemoglobin (Hb)A1c reductions with sodium glucose cotransporter inhibitors (SGLTis) and glucagon-like peptide (GLP)1 agonists, and modest improvements with metformin, dipeptidyl peptidase-4 inhibitor (DPP4i), and pramlintide. Studies exploring cardiovascular risk reduction are warranted. This review synthesizes the emerging literature for researchers and clinicians treating people with T1D. Challenges in T1D research are discussed.
中文翻译:
降低 1 型糖尿病死亡率:辅助治疗的作用?
1 型糖尿病 (T1D) 患者经常无法实现血糖目标,并且心血管风险过高和过早死亡。辅助药物可能在降低胰岛素治疗的发病率、死亡率和不良后遗症方面发挥作用。2 型糖尿病药物开发的激增揭示了药物具有降糖以外的益处,包括降低心血管风险。这些好处可以转化为 T1D 吗?针对 T1D 的特定试验表明,钠葡萄糖协同转运蛋白抑制剂 (SGLTis) 和胰高血糖素样肽 (GLP)1 激动剂可显着降低血红蛋白 (Hb)A1c,二甲双胍、二肽基肽酶 4 抑制剂 (DPP4i) 和普兰林肽可适度改善。探索降低心血管风险的研究是有必要的。本综述综合了研究人员和临床医生治疗 T1D 患者的新兴文献。讨论了 T1D 研究中的挑战。
更新日期:2020-02-01
中文翻译:
降低 1 型糖尿病死亡率:辅助治疗的作用?
1 型糖尿病 (T1D) 患者经常无法实现血糖目标,并且心血管风险过高和过早死亡。辅助药物可能在降低胰岛素治疗的发病率、死亡率和不良后遗症方面发挥作用。2 型糖尿病药物开发的激增揭示了药物具有降糖以外的益处,包括降低心血管风险。这些好处可以转化为 T1D 吗?针对 T1D 的特定试验表明,钠葡萄糖协同转运蛋白抑制剂 (SGLTis) 和胰高血糖素样肽 (GLP)1 激动剂可显着降低血红蛋白 (Hb)A1c,二甲双胍、二肽基肽酶 4 抑制剂 (DPP4i) 和普兰林肽可适度改善。探索降低心血管风险的研究是有必要的。本综述综合了研究人员和临床医生治疗 T1D 患者的新兴文献。讨论了 T1D 研究中的挑战。